Avexxin As

University of California

Efrosini Barbayianni

George Kokotos

Berit Johansen

Inger-Reidun Aukrust

Marcel Sandberg

Edward A Dennis

Samuel David

Violetta Constantinou-Kokotou

Marcel Sanderberg

Ruben Lopez-Vales

Victoria Magrioti

Daren Stephens

Athena Kalyvas

A compound of formula (I) wherein X is 0, C=0 or S; Y is N or CH; Rand Rare each independently H, &#x2014;(CH)COOH, &#x2014;(CH)CON(R)or &#x2014;(CH)COOCalkyl; or Rand Rtogether form a 6-membered phenyl ring fused to the five membered ring; each Ris independently selected from H, halo (e.g. fluoro or chloro), Caryl, Carylalkyl, Calkenyl; OCalkyl, OCalkenyl or a Calkyl group; each Ris H or Calkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.

Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds

A compound of formula (I) wherein X is O, C&#x2550;O or S;

Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds

Phospholipase A(PLA) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLAinhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA(cPLA) and/or Group VIA calcium independent PLA(iPLA) and/or Group V secreted PLA(sPLA). Pharmaceutical compositions of compounds having cPLAinhibitory activity (but not iPLAor sPLAinhibitory activity) are useful in treating multiple sclerosis, while compositions of compounds having sPLAinhibitory activity (as well as iPLAand CPLAactivity) are useful in treating spinal cord injuries (with related functional recovery).

Phospholipase A2 inhibitors and their use in treating neurological injury and disease

Growing community of inventors

Athens, Greece

Efrosini Barbayianni